Henry, Irene Monjo http://orcid.org/0000-0002-3252-8016
Fernández Fernández, E. http://orcid.org/0000-0002-1628-5042
Peiteado, D. http://orcid.org/0000-0002-6953-409X
Balsa, A. http://orcid.org/0000-0001-8070-7062
de Miguel, E. http://orcid.org/0000-0001-5146-1964
Article History
Received: 2 July 2022
Revised: 26 September 2022
Accepted: 19 October 2022
First Online: 11 November 2022
Declarations
:
: IMH: Speakers bureau: Roche, Novartis, UCB, Gedeon Richter; Consultant of: Roche. AB: Consultancies or speakers bureau: AbbVie, Pfizer, BMS, Nordic, Sanofi, Sandoz, Lilly, UCB, Roche, Galapagos, Gilead. EDM: Speakers bureau: AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grünenthal, Janssen, Sanofi; Paid instructor for: Janssen, Novartis, Roche; Consultant of: AbbVie, Novartis, Pfizer, Galapagos; Grant/research support from: AbbVie, Novartis, Pfizer. The other authors declare that they have no conflicts of interest.